Health Care & Life Sciences » Pharmaceuticals | Harbin Gloria Pharmaceuticals Co. Ltd.

Harbin Gloria Pharmaceuticals Co. Ltd. A | Mutual Funds

Mutual Funds that own Harbin Gloria Pharmaceuticals Co. Ltd. A

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
3,896,325
0.18%
0
0.04%
12/31/2017
Nanfang CSI 500 ETF
3,822,983
0.18%
-140,400
0.12%
12/31/2017
2,185,995
0.1%
-343,800
0.66%
12/31/2017
Vanguard Emerging Markets Stock Index Fund
2,133,075
0.1%
0
0%
07/31/2018
604,050
0.03%
604,050
0.12%
12/31/2017
562,798
0.03%
78,300
0.27%
12/31/2017
507,986
0.02%
-125,200
0.3%
12/31/2017
GF CSI 500 ETF
307,027
0.01%
-62,900
0.12%
12/31/2017
243,503
0.01%
-124,500
0.06%
12/31/2017
229,200
0.01%
43,800
0.63%
12/31/2017

About Harbin Gloria Pharmaceuticals Co.

View Profile
Address
No. 29 Beijing Road
Harbin Heilongjiang 150025
China
Employees -
Website http://www.gloria.cc
Updated 07/08/2019
Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research and development of biological products. It offers cardiovascular, cerebrovascular and skeletal muscular treatment, and antitumor and nutritional drugs. The company products include creatine phosphate sodium injections, clopidogrel bisulfate tablets, cerebroprotein hydrolysate injections, cervus and cucumis polypeptide injections, calcium levofolinate injections, and potassium and magnesium aspartate injections.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.